These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33687794)

  • 1. Rapid systemic uptake of naloxone after intranasal administration in children.
    Malmros Olsson E; Lönnqvist PA; Stiller CO; Eksborg S; Lundeberg S
    Paediatr Anaesth; 2021 Jun; 31(6):631-636. PubMed ID: 33687794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic Properties and Human Use Characteristics of an FDA-Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose.
    Krieter P; Chiang N; Gyaw S; Skolnick P; Crystal R; Keegan F; Aker J; Beck M; Harris J
    J Clin Pharmacol; 2016 Oct; 56(10):1243-53. PubMed ID: 27145977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International patent applications for non-injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database.
    McDonald R; Danielsson Glende Ø; Dale O; Strang J
    Drug Alcohol Rev; 2018 Feb; 37(2):205-215. PubMed ID: 28597483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal.
    Mundin G; McDonald R; Smith K; Harris S; Strang J
    Addiction; 2017 Sep; 112(9):1647-1652. PubMed ID: 28430384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study.
    McDonald R; Lorch U; Woodward J; Bosse B; Dooner H; Mundin G; Smith K; Strang J
    Addiction; 2018 Mar; 113(3):484-493. PubMed ID: 29143400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics after a single dose of naloxone administered as a nasal spray in healthy volunteers.
    Vanky E; Hellmundt L; Bondesson U; Eksborg S; Lundeberg S
    Acta Anaesthesiol Scand; 2017 Jul; 61(6):636-640. PubMed ID: 28444856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Intranasal vs Intramuscular Naloxone on Opioid Overdose: A Randomized Clinical Trial.
    Dietze P; Jauncey M; Salmon A; Mohebbi M; Latimer J; van Beek I; McGrath C; Kerr D
    JAMA Netw Open; 2019 Nov; 2(11):e1914977. PubMed ID: 31722024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of naloxone nasal spray 4 mg in the community setting: a survey of use by community organizations.
    Avetian GK; Fiuty P; Mazzella S; Koppa D; Heye V; Hebbar P
    Curr Med Res Opin; 2018 Apr; 34(4):573-576. PubMed ID: 28535115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Faster-Acting, Dry Powder-Based, Naloxone Intranasal Formulation for Opioid Overdose.
    Lapidot T; Bouhajib M; Faulknor J; Khan S; Krayz GT; Abrutzky C; Megiddo D
    Pharm Res; 2022 May; 39(5):963-975. PubMed ID: 35386013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of a novel, approved, 1.4-mg intranasal naloxone formulation for reversal of opioid overdose-a randomized controlled trial.
    Skulberg AK; Åsberg A; Khiabani HZ; Røstad H; Tylleskar I; Dale O
    Addiction; 2019 May; 114(5):859-867. PubMed ID: 30644628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous use of intranasal naloxone: A case of overdose reversal.
    Das S; Shah N; Ghadiali M
    Subst Abus; 2017; 38(1):18-21. PubMed ID: 27925864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal naloxone administration for treatment of opioid overdose.
    Robinson A; Wermeling DP
    Am J Health Syst Pharm; 2014 Dec; 71(24):2129-35. PubMed ID: 25465584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of knowledge and confidence following opioid overdose prevention training: A comparison of types of training participants and naloxone administration methods.
    Ashrafioun L; Gamble S; Herrmann M; Baciewicz G
    Subst Abus; 2016; 37(1):76-81. PubMed ID: 26514071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naloxone nasal spray - bioavailability and absorption pattern in a phase 1 study.
    Tylleskar I; Skulberg AK; Nilsen T; Skarra S; Dale O
    Tidsskr Nor Laegeforen; 2019 Sep; 139(13):. PubMed ID: 31556537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naloxone (Narcan) nasal spray for opioid overdose.
    Med Lett Drugs Ther; 2016 Jan; 58(1485):1-2. PubMed ID: 26714239
    [No Abstract]   [Full Text] [Related]  

  • 16. An increase in per-patient naloxone requirements in an opioid epidemic.
    Birmingham LE; Nielson JA
    Am J Emerg Med; 2017 Dec; 35(12):1958-1959. PubMed ID: 28633907
    [No Abstract]   [Full Text] [Related]  

  • 17. Naloxone without the needle - systematic review of candidate routes for non-injectable naloxone for opioid overdose reversal.
    Strang J; McDonald R; Alqurshi A; Royall P; Taylor D; Forbes B
    Drug Alcohol Depend; 2016 Jun; 163():16-23. PubMed ID: 26996745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of Pediatric Opioid Toxicity with Take-Home Naloxone: a Case Report.
    Lebin JA; Chen BC; Valento MJ
    J Med Toxicol; 2019 Apr; 15(2):134-135. PubMed ID: 30632074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NTNU intranasal naloxone trial (NINA-1) study protocol for a double-blind, double-dummy, non-inferiority randomised controlled trial comparing intranasal 1.4 mg to intramuscular 0.8 mg naloxone for prehospital use.
    Skulberg AK; Tylleskär I; Braarud AC; Dale J; Heyerdahl F; Mellesmo S; Valberg M; Dale O
    BMJ Open; 2020 Nov; 10(11):e041556. PubMed ID: 33184084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid widespread distribution of intranasal naloxone for overdose prevention.
    Madah-Amiri D; Clausen T; Lobmaier P
    Drug Alcohol Depend; 2017 Apr; 173():17-23. PubMed ID: 28182982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.